SASCHA ROTH FIGURED THAT WHEN have cancer in your colon and lymph nodes and your oncologist calls you after business hours, two days before you're scheduled to begin a brutal five-week course of radiation therapy, it's probably not good news-especially when the first thing she says is, "Are you sitting down?"
Roth was the first patient that enrolled into a clinical trial to test a new immunotherapy drug, designed to unleash the body's natural immune response on the tumor cells, on patients with early stage cancers. The results were miraculous: One hundred percent of the patients went into total remission-perhaps the first time that's ever happened in any cancer clinical trial, according to Luis Diaz, head of the division of solid tumor oncology in Memorial Sloan Kettering's Department of Medicine and a designer of the trial. The trial suggested the new therapies, if delivered early enough, might not only obviate the need for traditional therapies notorious for their brutal side effects, like chemo, radiation and surgery. They could potentially cure the disease altogether.
Roth's doctor was jubilant: "We've reviewed all your scans, biopsies-everything," she says the doctor told her. "There is zero sign of cancer. We can't radiate you knowing there's no cancer in your body."
The trial, published last year in The New England Journal of Medicine, electrified the field of cancer research and held out the promise of a powerful new approach that might help relieve many people from the suffering and anxiety caused by a scourge that kills 610,000 people each year in the U.S.
Denne historien er fra December 01 - 08, 2023 (Double Issue)-utgaven av Newsweek US.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra December 01 - 08, 2023 (Double Issue)-utgaven av Newsweek US.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Terry Crews
FOR TERRY CREWS, THERE ARE NO RULES.
Carrie Coon
CARRIE COON IS HAVING A MOMENT, EVEN THOUGH YOU MAY NOT RECognize her.
Still Doin' It Well
Ahead of the release of his new album, The FORCE, LL Cool J told Newsweek of his strong desire to keep contributing to the hip-hop culture he helped create
WORLD'S MOST TRUSTWORTHY COMPANIES 2024
TRUST IS AN ESSENTIAL PART OF ANY RELATIONSHIP-FROM PERsonal relationships to ties between businesses and consumers.
HOPE and HEALING on HORSEBACK
IT'S BEEN A DECADE SINCE ISIS COMMITTED GENOCIDE AGAINST IRAQ'S YAZIDI POPULATION. MORE THAN 100,000 YAZIDIS REMAIN DISPLACED BUT WORKERS AND ANIMALS AT AN EQUINE THERAPY CENTER ARE PROVIDING RELIEF
Is College Worth It?
AMERICANS are LOSING FAITH in HIGHER EDUCATION amid RISING TUITION FEES, UNCERTAIN PAYOFF and CULTURE WARS on CAMPUS
An integrated model for water management
Alkhorayef Water and Power Technologies has deep expertise and synergistic capabilities across the full water and wastewater value chain
Investments that are transforming life in Saudi Arabia
Abdullah Al Othaim Investment Company is creating distinctive destinations and experiences that encompass multiple sectors
A Kinder and Gentler Nick Cave
After a period of personal upheaval, the famed Bad Seeds singer returns with the vibrant and optimistic 'Wild God'
Fleeing War and Scams
Newsweek spoke to three Ukrainians who have been targeted by \"sponsors\" trying to profit from applicants seeking refuge in the U.S. via a humanitarian scheme